UnitedHealth Q2 Earnings Preview: Expecting EPS of $4.48 and Revenue of $111.5 Billion

UnitedHealth (UNH) is set to report Q2 earnings on July 29, with a 34% YoY decrease in earnings per share expected at $4.48. Revenues are expected to increase by 13% to $111.5 billion. The stock has dropped 43.8% YTD due to issues including suspension of guidance, escalating medical costs, and leadership shakeup. Analysts remain optimistic, with J.P. Morgan and Leerink Partners maintaining Buy ratings despite near-term uncertainty. Options traders expect a 7.97% move in either direction immediately after earnings.

UnitedHealth Group Incorporated (UNH) is poised to release its second-quarter 2025 earnings on July 29, 2025, before the opening bell. Analysts anticipate a significant decrease in earnings per share (EPS), with estimates projecting a 34% year-over-year (YoY) decline to $4.48 per share. Revenue growth, however, is expected to be robust, with projections suggesting a 13% YoY increase to $111.5 billion. The stock has experienced a tumultuous year, with a 43.8% year-to-date (YTD) drop, largely attributed to the suspension of financial guidance, escalating medical costs, and leadership shakeups [1].

The Zacks Consensus Estimate for earnings per share in the second quarter of 2025 indicates a decrease of 27.4% from the year-ago period. This decline is accompanied by an expected year-over-year revenue growth of 12.9% [1]. UnitedHealth's Medicare Advantage program is under investigation by the U.S. Department of Justice (DOJ), adding to the company's challenges. The company has pledged cooperation with the DOJ while maintaining confidence in its practices [2].

Despite near-term uncertainty, analysts remain optimistic. J.P. Morgan and Leerink Partners have maintained their Buy ratings for the stock. Options traders are positioning for a substantial move immediately following the earnings announcement, with expectations of a 7.97% move in either direction [1].

The company's second-quarter performance is expected to benefit from higher premium revenues and service revenues from the Optum brand. UnitedHealthcare's total domestic commercial customers and Medicare Advantage members are projected to show year-over-year growth, contributing to the overall revenue increase [1].

UnitedHealth Group's stock price has been volatile, dropping an additional 5% on July 24, 2025, following the recent disclosure of the DOJ investigation. The company's Medicare and retirement segment, including Medicare Advantage, generated $139 billion in sales last year, adding to the scrutiny [2].

In conclusion, UnitedHealth Group's Q2 earnings report is set to provide insights into the company's performance amidst a challenging year. The market is closely watching for any signs of recovery or further setbacks. Investors should stay informed and monitor the company's response to the DOJ investigation and other ongoing challenges.

References:
[1] https://ca.finance.yahoo.com/news/unitedhealth-thin-ice-q2-earnings-154200188.html
[2] https://dallasexpress.com/national/unitedhealths-medical-mess-cyberattacks-stock-plunge-and-doj-medicare-probe/